The potential health economic impact within the US was previously unknown. However, the current study reports the incremental cost-effectiveness of HOT-HMV in patients with hypercapnic COPD.2 The original trial data were used to develop an economic model, and findings were featured at the 2018 ATS International Conference in an abstract poster presentation from the payer perspective for both the U.S. and the UK.
The base-case incremental cost/QALY (quality adjusted life year) gained was negative $50,856,suggesting HOT-HMV as a dominant strategy (less expensive and more effective). Costs for HOT-HMV patients were $4,298 for devices, $10,805 for doctor visits, $758 for medication and $8,598 for exacerbations. HOT alone had the following costs: $1,582 for devices, $15,033 for doctor visits, $1,088 for medication and $10,683 for exacerbations.
In addition to the clinical effectiveness of HOT-HMV as previously reported, this data support cost effectiveness as well.